Alzheimer’s Disease And Dementia
Sleep behavior and irritability may be early noncognitive symptoms of Alzheimer's dementia.
Epileptic phenomena are an important component of the dysfunction of the neuronal networks affected by Alzheimer's disease.
A history of 2 or more vascular risk factors assessed at baseline in the ARIC study was associated with a significantly higher rate of amyloid deposits on PET scans at last visit.
Participants with the Met allele lost memory and cognitive skills more rapidly than those without the gene mutation.
Patients previously diagnosed with depression or anxiety did not have a greater risk of Alzheimer's.
Clinicians must keep this potentially increased risk in mind when prescribing long-term use of a specific anticholinergic drug to patients with DM suffering from OAB.
The association between intracranial atherosclerotic disease and dementia should be the focus of future studies.
Benzodiazepines increase risk for pneumonia-associated hospitalization, mortality in patients with Alzheimer disease.
Non-demented elderly patients experiencing excessive daytime sleepiness may be at increased risk for β-amyloid accumulation.
Females with Alzheimer's disease, the APOE4 gene, and comorbid Lewy bodies were more likely to experience psychosis.
No changes in imaging biomarkers including rates of edema or hemorrhage, or changes to whole brain volumes or hippocampal volumes were observed.
After controlling for comorbidities and demographics, there was no significant difference in dementia incidence in the study groups.
Independent risk factors for pneumonia included age, male gender, and underlying cerebrovascular disease.
A behavioral interventions program for Alzheimer's patient caregivers did not increase health costs.
Patients with the K-variant of the butyrylcholinesterase gene have an adverse reaction to treatment with donepezil.
Mixed AD neuropathologic changes were more frequent than pure ADNC pathology among the group that remained MCI until death.
Early intervention in patients with heart failure or atrial fibrillation may help delay or prevent the onset of mild dementia.
Ronald Petersen, MD, PhD, discusses the implications of Eli Lilly's failed solanezumab trial on the future of Alzheimer's disease research.
In people who are genetically at-risk for Alzheimer's, concussions appear to accelerate brain changes associated with the disease.
Increasing severity of AD pathology inversely correlated to decreases in time from motor symptoms to dementia onset and death.
Hormone therapy may reduce risk for death from vascular dementia in older women.
Amyloid beta protein accumulation was present in the hearts of patients with Alzheimer's disease.
There is a clear lack of evidence in the pharmacologic guidance of sleep problems in dementia.
Patients with Alzheimer's disease tended to have increased thickness in the wall of their left ventricle.
The present findings, in combination with those from prior observational research, provide a solid rationale for further randomized trials.
There seems to be no effect on everyday functioning.
Eli Lilly's investigational Alzheimer's drug failed to meet the primary end point in the phase 3 EXPEDITION3 trial.
Higher levels of education and better management of cardiovascular risk factors may have contributed to this improvement.
Patients with mild cognitive impairment with preserved hippocampal volume are at increased risk for dementia with Lewy bodies vs Alzheimer disease.
Future studies should investigate other neuropsychiatric factors for their impact on early signs of AD.
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Telestroke Treatment With IV tPA: How Long Is the Window of Opportunity?
- Hypothalamus May Play a Central Role in Chronic Migraine
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia
- The Handoff: Your Week in Neurology News - 5/25/17
- In Multiple Sclerosis, Hand Strength May Indicate Disease Status